BiomedicineNews.net

Biomedicine Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Ematobase.it

Gene therapy for AADC deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons


Aromatic L-amino acid decarboxylase ( AADC ) deficiency is a rare genetic disorder characterized by deficient synthesis of dopamine and serotonin. It presents in early infancy, and causes severe developmental disability and lifelong motor, behavioral, and autonomic symptoms including oculogyric crises ( OGC ), sleep disorder, and mood disturbance.

Researchers have investigated the safety and efficacy of delivery of a viral vector expressing AADC ( AAV2-hAADC ) to the midbrain in children with AADC deficiency.

Seven children, aged 4–9 years underwent convection-enhanced delivery ( CED ) of AAV2-hAADC to the bilateral substantia nigra and ventral tegmental area ( total infusion volume: 80 microL per hemisphere ) in 2 dose cohorts: 1.3 × 10(11) vg ( n = 3 ), and 4.2 × 10(11) vg ( n = 4 ).

Primary aims were to demonstrate the safety of the procedure and document biomarker evidence of restoration of brain AADC activity.
Secondary aims were to assess clinical improvement in symptoms and motor function.

Direct bilateral infusion of AAV2-hAADC was safe, well-tolerated and has achieved target coverage of 98% and 70% of the substantia nigra and ventral tegmental area, respectively.

Dopamine metabolism was increased in all subjects and FDOPA uptake was enhanced within the midbrain and the striatum.

Oculogyric crises resolved completely in 6 of 7 subjects by month 3 post-surgery.

Twelve months after surgery, 6/7 subjects gained normal head control and 4/7 could sit independently.

At 18 months, 2 subjects could walk with 2-hand support.

Both the primary and secondary endpoints of the study were met.

In conclusion, midbrain gene delivery in children with AADC deficiency is feasible and safe, and leads to clinical improvements in symptoms and motor function. ( Xagena )

Pearson TS et al, Nature Communications 2021; 12: 4251

XagenaMedicine_2021



Indietro